Cost comparison of F(ab’) 2 and Fab antivenoms for pit viper envenomation in the United States: a real-world analysis
Expert Review of Pharmacoeconomics & Outcomes Research · 2025
DOI: 10.1080/14737167.2025.2462236 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Walter Garcia-Ubbelohde und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorios Silanes, Ciudad de México, CDMX, Mexico. Hauptthemen laut MEDLINE: Snake Bites, Antivenins, Immunoglobulin Fab Fragments, Health Care Costs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Rare Disease Therapeutics.
Abstract (Originalsprache)
BACKGROUND: This study compared healthcare resource utilization (HCRU) and cost among patients treated for pit viper envenomation with Fab or F(ab')2 antivenom in the United States. RESEARCH DESIGN AND METHODS: Patients administered Fab or F(ab')2 between January 2019 and September 2022 were identified from IQVIA's New Data Warehouse and placed into two mutually exclusive cohorts. Inverse probability of treatment weighting (IPTW) was used to adjust for baseline differences between cohorts. All-cause HCRU and cost were assessed in the 6-months following antivenom administration (post-index) and compared between IPTW-adjusted cohorts. RESULTS: In total, 242 and 98 patients receiving Fab and F(ab')2 were identified, respectively. Pre-IPTW adjustment, cohorts differed on demographics and select comorbidities (standardized mean difference [SMD] ≥0.10). Post-IPTW, most variables were balanced (SMD < 0.01). Post-index total (Fab: $70,994; F(ab')2: $55,324), medical ($69,162; $52,339), and inpatient costs ($49,466; $29,730) were higher among Fab than F(ab')2 patients (all p < 0.05). After multivariable adjustment, the total (cost ratio [CR]: 0.83; 95% confidence interval [CI]: 0.70-0.98), inpatient (CR: 0.63; 95% CI: 0.51-0.79), and inpatient pharmacy costs (CR: 0.48; 95% CI: 0.33-0.68) were lower in the F(ab')2 than Fab cohort. CONCLUSIONS: Patients administered Fab had higher post-index total, inpatient, and inpatient pharmacy costs than patients administered F(ab')2 AV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorios Silanes, Ciudad de México, CDMX, Mexico.
- IQVIA, Falls Church, VA, USA.
- Rare Disease Therapeutics, Inc., Franklin, TN, USA.
- IQVIA, Wayne, PA, USA.
- Department of Emergency Medicine, The University of Arizona, College of Medicine - Tucson, Tucson, AZ, USA.
- Arizona Poison and Drug Information Center, The University of Arizona, R. Ken Coit College of Pharmacy, Tucson, AZ, USA.
Förderung
- Rare Disease Therapeutics
Zitieren
APA
Garcia-Ubbelohde, W., Pizzicato, L., Boesen, K. J., Munnangi, S., Shi, L., Hurst, N. B., & DeKoven, M. (2025). Cost comparison of F(ab’) 2 and Fab antivenoms for pit viper envenomation in the United States: a real-world analysis. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2462236
Vancouver
Garcia-Ubbelohde W, Pizzicato L, Boesen KJ, Munnangi S, Shi L, Hurst NB, et al. Cost comparison of F(ab’) 2 and Fab antivenoms for pit viper envenomation in the United States: a real-world analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2025.2462236
BibTeX
@article{GarciaUbbelohde2025,
author = {Garcia-Ubbelohde, Walter and Pizzicato, Lia and Boesen, Keith J and Munnangi, Swapna and Shi, Liucheng and Hurst, Nicholas B and DeKoven, Mitchell},
title = {Cost comparison of F(ab’) 2 and Fab antivenoms for pit viper envenomation in the United States: a real-world analysis},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2025},
doi = {10.1080/14737167.2025.2462236}
}
EUVIMED